SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Neogenomics Inc – ‘8-K’ for 2/27/20

On:  Monday, 3/2/20, at 5:19pm ET   ·   For:  2/27/20   ·   Accession #:  1077183-20-28   ·   File #:  1-35756

Previous ‘8-K’:  ‘8-K’ on / for 2/27/20   ·   Next:  ‘8-K’ on / for 4/9/20   ·   Latest:  ‘8-K/A’ on 2/26/24 for 2/16/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/02/20  Neogenomics Inc                   8-K:7,9     2/27/20   13:4.4M

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     31K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     34K 
12: R1          Cover                                               HTML     49K 
 8: XML         IDEA XML File -- Filing Summary                      XML     12K 
 9: XML         XBRL Instance -- neo-20200227_htm                    XML     22K 
11: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.CAL  XBRL Calculations -- neo-20200227_cal                XML      7K 
 5: EX-101.DEF  XBRL Definitions -- neo-20200227_def                 XML      9K 
 6: EX-101.LAB  XBRL Labels -- neo-20200227_lab                      XML     70K 
 7: EX-101.PRE  XBRL Presentations -- neo-20200227_pre               XML     34K 
 3: EX-101.SCH  XBRL Schema -- neo-20200227                          XSD     12K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    18K 
13: ZIP         XBRL Zipped Folder -- 0001077183-20-000028-xbrl      Zip     23K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:  C: 
  neo-20200227  
 i 0001077183 i FALSE00010771832020-02-272020-02-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549 
 
FORM  i 8-K  
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
 i February 27, 2020
 
 i NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter) 
 
 i Nevada
 i 74-2897368
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
 
 i 12701 Commonwealth Drive,  i Suite 9, i Fort Myers, i Florida i 33913
(Address of principal executive offices)(Zip Code)
 i (239)  i 768-0600
(Registrant’s telephone number, including area code) 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 i 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 i 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 i 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 i 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:Trading Symbol(s):Name of each exchange on which registered:
 i Common Stock, par value $0.001 per share i NEO i The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  i 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 




Item 7.01Regulation FD Disclosure.
NeoGenomics, Inc. (the “Company”) has made available an Investor Presentation, which is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
 
(a) Not applicable
(b) Not applicable
(c) Not applicable
(d) Exhibits.

99.1  
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
NEOGENOMICS, INC.
By:
/s/ Kathryn B. McKenzie
Kathryn B. McKenzie
Chief Financial Officer
March 2, 2020



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:3/2/204
For Period end:2/27/208-K
 List all Filings 
Top
Filing Submission 0001077183-20-000028   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 2:53:33.1am ET